Interpreting Registrational Clinical Trials of Biological Therapies in Adults with Inflammatory Bowel Diseases.

Date publication

novembre 2016

Journal

Inflammatory bowel diseases

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Ghosh S, Sandborn WJ, Colombel JF, Feagan BG, Panaccione R, Hanauer S, Schreiber S, Peyrin-Biroulet L, Vermeire S, Eichner S, Huang B, Robinson AM, Pappalardo B

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/27585411

Résumé

The use of biologics to treat inflammatory bowel disease is supported by robust randomized controlled trials in both ulcerative colitis and Crohn's disease. Nonetheless, an understanding of the principles of clinical trial design is necessary to extrapolate study findings to clinical practice.

Mots clés

Adult, Biological Therapy, methods, Colitis, Ulcerative, therapy, Crohn Disease, therapy, Data Interpretation, Statistical, Humans, Randomized Controlled Trials as Topic, Research Design

Référence

Inflamm. Bowel Dis.. 2016 11;22(11):2711-2723